Simple Summary
The lungs are continuously exposed to changing oxygen levels, and their cells rely on oxygen-sensing pathways to maintain normal function and respond to injury. Hypoxia-inducible factor 2 alpha is a key component of this system. It is already a proven drug target in cancer. Recent studies suggest that it also has important and sometimes opposing roles in lung health and disease. In some settings, hypoxia-inducible factor 2 alpha supports lung development, protects blood vessel barriers, and helps maintain the delicate interface where oxygen passes from the lungs into the blood. In others, persistent or misplaced activity may contribute to pulmonary hypertension, lung scarring, abnormal repair, and changes in immune-cell function. Human studies of adaptation to life at high altitude also show that this pathway can be finely adjusted rather than simply turned on or off. This review brings these findings together and considers how they could guide future treatments. The evidence suggests that successful therapies may need to account for which lung cells are involved and whether the goal is to reduce harmful activity or preserve beneficial functions.
Abstract
Hypoxia-inducible factor 2α (HIF-2α), encoded by EPAS1, has long been studied in erythropoiesis, high-altitude adaptation, and cancer. Recent studies also implicate HIF-2α within non-malignant lung development and disease. This review examines HIF-2α as a dosage-sensitive, context-dependent regulator of lung cell state rather than a uniformly protective or pathogenic transcription factor. HIF-2α inhibitors have been approved in oncology, while pulmonary studies demonstrate roles for HIF-2α in fetal lung maturation, endothelial barrier integrity, alveolar–capillary maintenance, pulmonary vascular remodeling, aberrant epithelial repair, fibroblast persistence, airway differentiation, and alveolar macrophage metabolic and surfactant homeostasis. We summarize the canonical EGLN/PHD–VHL–HIF pathway, the HIF-1α/HIF-2α isoform bias, human genetic evidence from chronic hypoxia adaptation, and emerging disease-specific data in pulmonary arterial hypertension, pulmonary fibrosis, COPD/emphysema, acute lung injury/ARDS, and muco-obstructive disease. We also highlight chromatin, long noncoding RNA, and post-transcriptional mechanisms that tune HIF-2α activity. Together, these findings support the need to precisely tailor HIF-2α modulation in lung disease, guided by cell type, disease phase, spatial context, and biological objective.